Literature DB >> 9466476

Dose-dependent effect of diaspirin cross-linked hemoglobin on regional blood circulation of severely hemorrhaged rats.

A Gulati1, A P Sen.   

Abstract

Diaspirin cross-linked hemoglobin (DCLHb), a hemoglobin-based blood substitute, has been found to improve systemic hemodynamics, cutaneous oxygen tension, and normalization of blood lactate levels and acid-base equilibrium after hemorrhage in animals. The present study was conducted to determine the dose-dependent effect of a 10% solution of DCLHb (20, 50, and 100% of shed blood volume; SBV) on regional blood circulation in hemorrhaged rats. Hemorrhage was induced in urethane-anesthetized rats by bleeding them at a rate of approximately .5 to 1 mL/min until a mean arterial pressure of 35-40 mmHg was achieved. This was maintained for up to 90 min to reach a base deficit of more than -12 mmol/L. Hemorrhage significantly decreased oxygen consumption, mean arterial pressure, cardiac output, stroke volume, and regional blood circulation, but increased total peripheral resistance. The vehicle Ringer's lactate (RL at 20% of SBV, intravenously) did not produce any improvements in oxygen consumption, base deficit, systemic hemodynamics, and regional blood circulation. DCLHb increased oxygen consumption, decreased base deficit, and produced significant improvements in systemic hemodynamics and regional blood flow in a dose-dependent manner. The increase in blood flow was highly significant until 60 min, but was less marked at 120 min, after resuscitation with DCLHb. Resuscitation with RL (300% of SBV) significantly improved systemic and regional blood circulation. However, the improvement was greater after resuscitation with DCLHb (50 or 100% of SBV) as compared with RL at 300% SBV. DCLHb in the dose of 50% of SBV produced maximal resuscitative effects, which were comparable to a DCLHb dose of 100% of SBV. The effect of DCLHb at 50% of SBV on renal cortical blood perfusion, concentration of moving red blood cells (CMBC), and blood velocity was also studied using laser Doppler flowmetry. Hemorrhage produced a decrease in renal cortical blood perfusion (85.3%), which was due to a decrease in the CMBC (61.0%) and their velocity (64.2%). Resuscitation with the RL did not produce any improvement in renal cortical perfusion. However, resuscitation with DCLHb significantly increased renal cortical perfusion (364.7%) due to an increase in both CMBC (123.4%) and their velocity (109.9%). It is concluded that DCLHb in a dose of 50% of SBV produces maximal improvement in regional blood circulation of hemorrhaged rats.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9466476     DOI: 10.1097/00024382-199801000-00010

Source DB:  PubMed          Journal:  Shock        ISSN: 1073-2322            Impact factor:   3.454


  5 in total

1.  DCL-Hb for trauma patients with severe hemorrhagic shock: the European "On-Scene" multicenter study.

Authors:  Thoralf Kerner; Olaf Ahlers; Siegfried Veit; Bruno Riou; Michael Saunders; Ulrich Pison
Journal:  Intensive Care Med       Date:  2003-01-23       Impact factor: 17.440

2.  Resuscitative Effect of Centhaquine (Lyfaquin®) in Hypovolemic Shock Patients: A Randomized, Multicentric, Controlled Trial.

Authors:  Anil Gulati; Dinesh Jain; Nilesh Radheshyam Agrawal; Prashant Rahate; Rajat Choudhuri; Soumen Das; Deba Prasad Dhibar; Madhav Prabhu; Sameer Haveri; Rohit Agarwal; Manish S Lavhale
Journal:  Adv Ther       Date:  2021-05-10       Impact factor: 3.845

Review 3.  Blood substitutes. Haemoglobin therapeutics in clinical practice.

Authors:  J F Baron
Journal:  Crit Care       Date:  1999-09-28       Impact factor: 9.097

4.  Comparative In Vivo Effects of Hemoglobin-Based Oxygen Carriers (HBOC) with Varying Prooxidant and Physiological Reactivity.

Authors:  Vlad Al Toma; Anca D Farcaș; Ioana Roman; Bogdan Sevastre; Denisa Hathazi; Florina Scurtu; Grigore Damian; Radu Silaghi-Dumitrescu
Journal:  PLoS One       Date:  2016-04-20       Impact factor: 3.240

5.  A Multicentric, Randomized, Controlled Phase III Study of Centhaquine (Lyfaquin®) as a Resuscitative Agent in Hypovolemic Shock Patients.

Authors:  Anil Gulati; Rajat Choudhuri; Ajay Gupta; Saurabh Singh; S K Noushad Ali; Gursaran Kaur Sidhu; Parvez David Haque; Prashant Rahate; Aditya R Bothra; Gyan P Singh; Sanjiv Maheshwari; Deepak Jeswani; Sameer Haveri; Apurva Agarwal; Nilesh Radheshyam Agrawal
Journal:  Drugs       Date:  2021-06-01       Impact factor: 9.546

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.